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A B S T R A C T  
Pirmenol enant iomers  in dog plasma were quantit ied using a stcrcospccific high-perfornlance liquid 
chromatograph ic  method  with ,dtraviolet detect ion at 262 nm. Racemic pirmenol and internal s tandard,  
( + ) -propranolol ,  were isolated t tom dog plasma by a three-step cxtr:tction procedure  using toluene, 0.1 M 
hydrochlor ic  acid and hexane, lespcctivcly. A chiral analytical column (Chiralcel O J) was used with a 
mobile phase consisting o fhexan t , - i sopropanol -d ie t lwlamine  (98.9: !.0:0. I ). Linear  calibration curves were 
obta ined in the concent ra t ion  range 0.0200-5.00 l~g/ml for each enant iomer .  Precision o f  the method,  
expressed as coefticient o f  variat ion for nine quali ty control  samples, was 7. i % For ( + )-pirmenol and 6.4% 
for ( - ) - p i r m e n o l .  Bias was • 2.2~/o for ( + ) - p i r m e n o l  and 4- 1.5% for ( - ) - p i r m e n o l  in quali ty control  
samples. 
I N T R O D U C T I O N  
Pirmenol,  ( 4- ) -c is -oc-[3-(2 ,6-dimethyl -  l-piperidinyl)propyl]-7- phenyl-2-pyri- 
dinemethanol  monohydrochlor ide  monohydrate ,  is a chiral c o m p o u n d  (Fig. 1) 
being investigated as an antiarrhythmic agent. Pirmenol ;s administered as a 
racemic mixture and its pharmacokinetics  have been studied in healthy subjects 
and patients with dysrhythmia [I-4]. Analytical methods  used for these studies 
quantified pirmenol as a racemi,: mixture without distinguishing between 
enantiomers [5,6]. Investigatior~ of  possible stereoselective differences in pharma- 
cokinetics,  metabol ism and pharmacodynamics  o f  pirmenol requires a n':.ethod 
for quantitation of  its enantiomers in biological samples. 
~CH3 OH 
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Fig. 1. Structure o f  pirmenol (CI-845). The ast,:risk de:~otes the location o f  the chiral center.  
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Since derivatization of pirmenol  was not  successful, several chiral columns 
were investigated for the separat ion of  pirmenol enantiomers.  A chiral Hypro-  
Cu-Daltosil  column (Serva, New York,  NY, USA) was first tried since it was 
reported to separate pirmenol enant iomers  in dog and human urine [7]. However,  
this column did not provide adequate  separat ion at typical racemic pirmenol 
concentrat ions in plasma ( <  1.0 Itg/ml) following therapeutic doses. An ~ - a c i d  
glycoprotein column (LKB Enant ioPac,  Bromma,  Sweden) also separated pirme- 
nol enantiomers,  but racemic concentrat ions less than 0.5 Itg/rnl could not be 
quantified accurately. For  pharmacokinet ic  studies, a detection limit of  at least 
0.1 ltg/ml racemic pirmenol would be required. 
The method described uses cellulose tr is(4-methylbenzoate) adsorbed on siW.ica 
gel [8] as a chiral s ta t ionary phase (Chiralcel O J, Daicel, Tokyo,  Japan)  for sep- 
arat ion of  pit menol enantiomers.  Linearity, precision and accuracy were evaluat- 
ed following analysis of  calibration s tandards and quality control  samples pre- 
pared in dog plasma. Possible differences in the pharmacokinet ics  and 
pharmacodynamics  of  each enant iomer  are currently being evaluated using this 
high-performance liquid chromatographic  (HPLC)  method for quant i ta t ion  of  
(+ ) -p i rmeno l  and ( - ) - p i r m e n o l  in plasma. 
E X P E R I M E N T A L  
Chemicals 
Racemic pirrnenol hydrochlor ide and pirmenol free base were synthesized, and 
pirmenol enantiomers were separated at the Parke-Davis  Pharmaceutical  Re- 
search Division, Warner  Lamber t  (Ann Arbor,  MI,  USA). Internal  s tandard  
used for the assay was ( + ) - p r o p r a n o l o l  hydrochloride (Sigma, St. Louis, MO,  
USA). Mobile phase consisted of  HPLC-grade  hexane (EM Science, Gibbstown,  
N J, USA), HPLC-grade isopropanol  (Baxter, Burdick and Jackson Division, 
Muskegon,  MI, USA) and diethylamine (Sigma). Glassware was silanized using a 
i0% solution of  dichlorodilnethy!silane (Sigma) in HPLC-grade  toluene (Baxter, 
Burdick and Jackson Division). t-Iydrochloric acid and sodium hydroxide solu- 
tions were prepared, using s tandard volumetric solutions purchased from J. T. 
Baker (Phillipsburg, N J, USA) with HPLC-grade  water (EM Science). Control  
beagle dog plasma was obtained at the Parke-Davis  Pharmaceut ical  Research 
Division, Warner  Lambert .  Control  human  plasma was purchased from Inter- 
state Blood Bank (Memphis,  TN,  USA). 
Prep¢:,'ation o./" sohttions 
A 250 l~g/ml stock solution of racemic pirmenol and a 100 ltg]ml stock solu- 
tion of  (+ ) -p rop rano lo l  were prepared in 0.01 M hydrochloric  acid using silan- 
ized volumetric flasks. A 25 tlg/ml racemic pirmenol stock solution was prepared 
by  dilution (1:I0) of  the 250 ttg/ml stock solution. Concentra t ions  represent free 
base equivalents. Stock solutions were diluted with 0.01 M hydrochloric  acid for 
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prepa ra t ion  o f  ca l ib ra t ion  s t andards  in s i lanized vo lumet r ic  flasks. Concen t ra -  
t ions o f  p i rmenol  enan t iomer s  in ca l ib ra t ion  s t anda rd  solut ions  ranged f rom 
0.100 to 25.0 ttg/ml. In te rna l  standar,~ solut ion (2.50 / lg/ml) was p repared  by 
d i lu t ion  (! :40) o f  in te rna l  s t anda rd  stock solut ion with 0.01 M hydroch lor ic  acid. 
Qua l i ty  con t ro l  samples  con ta in ing  racemic  p i rmeno i  were prepared  at 0.0600, 
0.300 and  1.50 l~g/ml o f  each enan t iomer .  A p p r o p r i a t e  vo lumes  of  25 or 250 
lLg/ml stock so lu t ions  were added  to silmz,zed 25-mi vo lumet r ic  flasks and  
b rough t  to vo lume  wi th  cont ro l  beagle  clog l~,asma. Al iquo t s  o f  qua l i ty  cont ro l  
samples  were s tored at - 15"C in s i lanized glass tubes. 
Extraction procedure 
For  ca l ib ra t ion  s t andards ,  0.5 ml o f  control  dog p l a s m a  and  0.1 ml o f  cali- 
b ra t ion  s t anda rd  so lu t i on  con ta in ing  racemic  p i rmeno l  were combined  in a 100 
m m  x 16 m m  d isposab le  glass cul ture  tube.  A 0.5-ml a l iquot  o f  dog p l a sma  and  
0.1 ml o f  0.01 M hydroch lo r i c  acid were used for qua l i ty  cont ro ls  and s tudy 
samples .  A 0.1-ml a l iquot  o f  2 .5 / tg /ml  in ternal  s t anda rd  solut ion and  0.2 mi o f  1 
M sod ium hydrox ide  were added  to each tube. T he  mix ture  was extracted with 5 
ml o f  to luene by shak ing  for  10 rain, cent r i fuged at 750 g for 5 rain, and  the 
aqueous  layer  was frozen in a dry  ice-ace tone  bath.  T he  r ema in ing  toluene was 
t ransfer red  to a 15-ml d i sposab le  glass centr i fuge tube, back-ext rac ted  with 0.5 ml 
o f  0. I M hydroch lo r i c  acid by shak ing  for 10 min  and centr i fuged at 420 g for 5 
rain. T h .  ~ aqueous  layer  was frozen in a dry ice-ace tone  ba th  and  tc luene  was 
discarded.  Af te r  thawing ,  0.2 ml  o f  1 M sod ium hydrox ide  was added  and  the 
mix ture  was extracted with hexane  by shak ing  for  10 rain fol lowed by centr ifu-  
ga t ion  at 420 g for 5 rain. The  aqueous  layer  was frozen in a dry  ice-ace tone  ba th  
and  hexane  was  t ransfer red  to a s i lanized 75 m m  × 12 m m  disposable  glass 
cul ture  tube.  H e x a n e  was evapora ted  under  n i t rogen gas and  the residue was 
dissolved in 200 ~tl o f  mobi l e  phase.  A 175-ltl a l iquot  was injected into the H P L C  
system. 
Chromatography 
The  H P L C  system consis ted o f  a Mode l  590 solvent  del ivery module ,  a Mode l  
712 au tosample r ,  M o d e l s  C H M  and T C M  c o l u m n  tempera tu re -con t ro l l ing  sys- 
tem (Waters ,  Mi l fo rd ,  M A ,  USA),  and  a Mode l  8490 ul t raviole t  abso rbance  
detector  and  C h r o m j e t  in tegra tor  (Spectra-Physics ,  San Jose, CA,  USA).  
P i rmeno l  enan t iomers  and  in te rna l  s t andard  were separa ted  using a Chira lcel  
OJ c o l u m n  with 10 Ftm part ic le  size and  d imens ions  o f  25 cm x 4.6 mni  I.D. (J. T .  
Baker)  and  a mobi l e  phase  o f  h e x a n e - i s o p r o p a n o l - d i e t h y l a m i n e  (98.9:I.0:0.1, 
v/v). F low-ra te  was 1.0 ml ]min ,  c o l u m n  tempera tu re  was  m a i n t a i n e d  at 65"C, and  
abso rbance  was m o n i t o r e d  at 262 nm.  
Assay validation 
Cal ib r a t i on  s t anda rds  and  qua l i ty  control  samples  were ana lyzed  in tr ipl icate 
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on three separate days for a total of nine determinations at each concentration. 
Calibration standard concentrations ranged from 0.0200 to 5.00 ltg/ml for ( + ) -  
pirmenol and (--)-pirmenoI (0.0400-10.0 /Lg/ml racemic pirmenol). Pirmenol 
enantiomer concentrations in quality control samples of  dog plasma were 0.0600, 
0.300 and 1.50 /~g/ml (0.120, 0.600 and 3.00 /~g/ml racemic pirmenol). Least- 
squares linear regression with a weighting factor of 1/concentration was used to 
construct calibration curves for peak-height ratio as a function of pirmenol 
enantiomer concentration. Regression parameters (slope; y-intercept) were used 
to calculate (+)-pirmenol  and ( - ) -p i rmeno l  concentrations in calibration stan- 
dards, quality control samples and #7 vivo plasma samples. 
Reco l,erv 
Recovery of pirmenol enantiomers from dog plasma was determined at cali- 
bration standard concentrations of 0.0500, 0.250 and 2.50 ltg/ml (+)-pi rmenol  
and ( - )-pirmenol (0. 100, 0.500 and 5.00 llg/ml racemic pirmenol). Nine determi- 
nations were performed at each concentration. Peak heights of (+)-pirmenol ,  
( - ) -p i rmcno l  and internal standard following extraction from dog plasma were 
compared with n-man peak heights from nine injections of reference (non-extract- 
ed) standards. For  reference standards, stock solutions of racemic pirmenol free 
base in isopropanol and (+)-propranolol  hydrochloride (internal standard) in 
methanol were prepared. Aliquots of these stock solutions were pipetted into 
silanized volurnetric flasks, solvents were evaporated under nitrogen, and residue 
was dissolved in hexane-isopropano!-diethylamine (99.1:0.8:0.1, v/v). 
Dog pNsma samples 
A single 5 mg/kg intravenous dose of racemic pirmenoI was administered to 
two male beagle dogs. The dose was prepared in 0.9% saline and given as a 5-min 
infusion. Serial blood samples were obtained for 8 h following the end of  the 
infusion. After centrifugation, plasma was separated and stored frozen at - 15°C 
until assayed. Pirmenol enantiomer concentrations in dog plasma were deter- 
mined using the method described. Pharmacokinetic parameters were calculated 
using non-compartmental methods [9]. 
R E S U L T S  A N D  DiaL?USSION 
Chroma t ograldO, 
Representative chron-mtograms of  pirmenol enantiomers in dog plasma are 
shown in Fig. 2, where retention times of (+)-pirmenol ,  ( - ) -p i rmeno l  and in- 
ternal standard are 7.4, 9.2 and 20.9 min, respectively. No chromatographic 
peaks at retention times of pirmenol enantiomers or internal standard were ob- 
served in control dog plasma. In addition, control human plasma did not show 
any interfering peaks, sagg~sting that this method may also be applicable to 
human plasma samples. 
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Fig. 2. Chromatograms of  (a) control dog plasma with no pirmenol or internal standard added, (b) a 
calibration standard containing 0.500 ltg/ml (+)-pirmenol and (-)-pirmenol  (1.00/lg/ml racemic pirme- 
nol) and internal standard, and (c) a dog plasma sample obtained 45 min after the end o f a  5-min infusion 
of  5 mg/kg racemic pirmenol. Peaks: ( + )  -- ( + )-pirmenol; ( - )  = (-)-pirmenol;  IS = internal standard, 
(+)-propranolol.  
Elution order of enantiomers was identified by comparing retention times of 
(+)-pi rmenol  and (--)-pirmenol reference standards to retention from racemic 
pirmenol. 
Calibration standards 
Calibration curves were linear over the concentration range 0.0200-5.00 pg/ml 
for (+)-p i rmenol  and ( - ) -p i rmeno l  in dog plasma. Regression parameters 
(slope; y-intercept; coefficient of determination, r 2) calculated following analysis 
of  nine sets of calibration standards are shown in Table I. Variability of slope, as 
judged by coefficient of  variation, was less than 3.0% for both enantiomers. 
Mean calculated concentrations of calibration standards analyzed in triplicate 
on three separate days are shown in Table II. The coefficient of variation (C.V.) 
for nine determinations was 5.9% or less for (+)-p i rmenol  and 7.9% or less for 
( - ) -p i rmenol .  The bias, calculated as the percentage difference from theoretical 
concentration, was ± 3 . 5 %  for (+)-pi rmenol  and ± 5 . 5 %  for ( - ) -p i rmenol .  
Quality conlrols 
Table III contains mean calculated concentrations for quality control samples 
containing racemic pirmenol in dog plasma. Precision was at least 7.1% for each 
enantiomer in quality control samples, based on C.V. values for (+)-pi rmenol  
and ( - ) -p i rmenol .  Calculated concentrations were within 2.2% of actual concen- 
trations for both pirmenol enantiomers. Precision and accuracy were also eval- 
uated for the three determinations performed on each day (intra-day) and for 
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T A B L E  ! 
I N D I V I D U A L  A N D  M E A N  0t -~ 9) REt. , IRESSION P A R A M E T E R S  F O R  P I R M E N O L  
E N A N T I O M E R S  IN D O G  P L A S M A  F O L L O W I N G  A S S A Y  O F  C A L I B R A T I O N  S T A N D A R D S  IN 
T R I P L I C A T E  O N  T H R E E  S E P A R A T E  D A Y S  
Cal ib ra t ion  concenl ra t io l t s  ranged f rom 0.0200 to 5.00 /~g/ml ( + ) - p i r m e n o l  and  ( - ) - p i r m e n o l ;  r'- = 
coefficient o f  delermin,'Ltion. 
Day Curvc ( + )-Pirmen ol ( - ) -Pirmenol  
No. 
Slope ) ' - In le rcept  r z Slope y - In te rcep t  r z 
1 1 3.16 0.0174 0.9985 2.21 0.0051 
2 3.21 0.0169 0.9998 2.24 0.0017 
3 3.28 0.0141 0.9995 2.30 0.0028 
2 4 3.29 0.0294 0,9987 2.27 0.0127 
5" 3.30 0.0343 0.9994 2.27 0.0096 
6 3.16 0.0268 0.9997 2.20 0.0094 
3 7 3.26 0.0063 0.9998 2.26 - 0 . 0 0 3 4  
8 3.33 0.0041 0.9995 2.30 - 0.0020 
9 3.46 0.0078 0.9997 2.39 - 0.0030 
Mean 3.27 0.0175 0.9994 2.27 0.0037 












" Ca l ib ra t ion  s t anda rd  concen t ra t ions  ranged from 0.0250 to 5.00 Itg/ml p i rmenol  enant iomers .  
T A B L E  II 
M E A N  (n = 9) C A L C U L A T E D  C O N C E N T R A T I O N S  O F  ( + ) - P I R M E N O L  A N D  ( - ) - P I R M E N O L  
IN C A L I B R A T I O N  S T A N D A R D S  A N A L Y Z E D  !N T R I P L I C A T E  O N  T H R E E  S E P A R A T E  D A Y S  
Conccn-  ( + ) - P i r m e n o l  ( - ) - P i r m e n o l  
t ra t ion 
added  Mean  concen t ra t ion  C.V. Bias Mean  concen~.ration C.V. Bias 
(/tg/ml) found ( l tglml)  (%)  (%)  found (/tg/ml) (%) (%)  
0.0200 0.0193" 5.85 - 3.50 0.0189 5.77 - 5.50 
0.0250 0.0243 5.43 - 2.80 0.0238 7.94 - 4.80 
0 . 0 5 0 0  0.0509 4.99 1.80 0.0512 7.2I 2,40 
0.100 0.102 3.02 2.00 0.105 3.64 5.00 
0.250 0.253 2.75 1.20 0.255 3.84 2.00 
0 . 5 0 0  0 . 5 0 8  2 .13  1.60 0 . 5 0 9  2 . 2 4  ] . 8 0  
1.00 t.01 3.33 !.00 1.01 3.61 1.00 
2.50 2.48 2.94 -- 0.80 2.48 3.30 -- 0.80 
5.00 5.01 1.53 0.20 5.00 1.51 0.00 
' + n  = 8. 
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T A B L E  II1 
M E A N  (n = 9) C A L C U L A T E D  C O N C E N T R A T I O N S  O F  ( + ) - P l  R M E N O L  A N D  ( - ) - P I R M E N O L  
IN Q U A L I T Y  C O N T R O L  S A M P L E S  A N A L Y Z E D  IN T R I P L I C A T E  ON T H R E E  S E P A R A T E  
D A Y S  
Concen-  ( + ) - P i r m e n o l  ( - ) - P i r m e n o l  
t ra t ion 
added Mean  concent ra t ion  C.V. Bias Mean  concentra t ion  C.V. Bias 
(fig/nil) found (l~g/ml) (%)  (%)  found (itg/ml) (%)  (%) 
0.0600 0.0587 7.12 - 2.17 0.0609 6.44 1.50 
0.300 0.297 3.47 - 1.00 0,300 2. ! 8 0.00 
1.50 1.53 4.33 2.00 1.52 4.22 1.33 
calibration standards analyzed on each of three days (inter-day). Intra-day assay 
precision (C.V.) ranged from 1.0 to 8.5% for (+)-pi rmenol  and fi'om 0.7 to 8.9% 
for ( - ) -p i rmenol .  Intra-day assay accuracy (bias) was 4-9.3% for (+)-pirmenol  
and -4-4.7% for (--)-pirmenol. Inter-day assay precision (C.V.) ranged from 2.5 
to I0.5% and inter-day assay accuracy (bias) was within 4.2% for (+)-pirmenol.  
Inter-day precision (C.V.) ranged from !.5 to 9.5% and inter-day accuracy (bias) 
was within 4.7% for ( - ) -p i rmenol .  
Reco very 
Recovery of  pirmenol enantiomers and internal standard from dog plasma is 
shown in TaL',e IV. Mean (n = 9) recovery was approximately 80% for both 
pirmenol enantiomers over the concentration range 0.0500-2.50/tg/ml, with C.V. 
T A B L E  IV 
R E C O V E R Y  O F  P I R M E N O L  E N A N T I O M E R S  A N D  I N T E R N A L  S T A N D A R D  F R O M  D O G  
P L A S M A  
Recovery  is expressed as rat io  o f  peak  height for  ( + ) - p i r m e n o l ,  ( - ) - p i r m e n o l  or  internal stand;lrd after  
extract ion f rom dog p lasma to mean  peak height after nine injections o f  non-extracted s tandards .  
C o m p o u n d  n Concent ra t ion  Mean  recovery C.V. 
(~g/ml) (%) (%) . . . .  
( + )-Pirmenol  9 0.0500 79.6 7.2 I 
0.250 79.8 3.22 
2.50 77.9 3.8 I 
( - ) - P i r m e n o l  9 0.0500 83.9 6.83 
0.250 79.6 3.38 
2.50 77.4 3.94 
Internal  s tandard  27 0.500 73.5 3.76 
186 N. J A N I C Z E K  et  al. 
T A B L E  V 
STABILITY OF P I R M E N O L  E N A N T I O M E R S  IN D O G  P L A S M A  
V:dues tire expressed as percent o f  added (4-) -p i rmenol  or  ( - ) - p i r m e n o l  concentration in dog plasma 
qu:dity control samples stored at - 15*C until analysis." 
Concen-  Percentage remaining 
tration 
added ( + )-Pirmenol ( - )-Pirmenol 
(Hg/mi} 
Two monLhs Three  mon ths  F o u r  months  T w o  mon ths  Three months  F o u r  mon ths  
0.0600 93.3 93.0 96.7 103 94.0 97.3 
0.300 96.7 106 I09 ! 15 107 99.3 
1.50 96.7 101 96.0 96.7 102 96.7 
values o f  7 .2% or less. P irmenol  enant iomers  showed a slight decrease in recovery 
with increasing concentrat ion.  Mean  (n = 27) internal standard recovery was 
74%. 
Stability 
Stability data for pirmenol  enant iomers  in quality control  samples  are listed in 
Table V. These  values represent single determinations  o f  pirmenol  enant iomer 
concentrat ions  in quality controls  which were analyzed with study samples.  Pir- 
menol  enant iomers  showed no degradation and are considered stable in dog  
plasma stored at - 15°C for at least four months .  
Pirmenoi enantiomer pharmacokhletics in beagle dogs 
Fol lowing  intravenous administration o f  racemic pirmenol  (5 mg/kg)  to two 












Fig. 3. Plasma concen t r a t i on - t ime  profile for ( + ) - p i r m e n o l  ( O )  and ( - ) - p i r m e n o l  ( [ ] )  following a 5-rain 
intravenous infusion or  5 m g / k g  racemic pi rmenol  to a beagle dog, 
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concentrations. Fig. 3 shows a plasma concentration-t ime profile of  pirmenol 
enantiomers in a representative dog. In this animal, terminal-phase half-life was 
1.7 and 2.3 h for (+) -p irmeno!  and ( - ) - p i r m e n o l ,  respcctively. Plasma clearance 
was 33.3 ml /min/kg  for (+ ) -p irmeno l  and 25.6 ml /min/kg for (--)-pirmenol.  
CONCLUSION 
A normal-phase HPLC assay for pirmenol enantiomers has been developed 
and validated in dog plasma. Direct separation is achieved on a chiral stationary 
phase (Chiralcel O J) without derivatization. Calibration curves are linear in the 
concentration range 0.0200-5.00 ~ug/ml for ( + )-pirmenol and ( - )-pirmenoi. This 
method can be used for the pharmacoki,.'aetic evaluation of  pirmenol enantiomers 
in dogs following administration of  racemic pirmenol. 
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